Tasly Pharmaceutical Group (SHSE:600535) Seems To Use Debt Rather Sparingly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, whe

Simply Wall StMay 10 18:51 ET

Tasly Pharmaceutical Group (SHSE:600535) Is Posting Promising Earnings But The Good News Doesn't Stop There

The market seemed underwhelmed by last week's earnings announcement from Tasly Pharmaceutical Group Co., Ltd (SHSE:600535) despite the healthy numbers. Our analysis suggests that shareholders might b

Simply Wall StApr 22 18:39 ET

Tasly Pharmaceutical Group Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models

The analysts might have been a bit too bullish on Tasly Pharmaceutical Group Co., Ltd (SHSE:600535), given that the company fell short of expectations when it released its yearly results last week.

Simply Wall StApr 18 20:15 ET

Tasly Pharmaceutical Group Returns to Profit in 2023 as Operating Income Stays Flat

Tasly Pharmaceutical Group (SHA:600535) returned to an attributable profit of 1.07 billion yuan in 2023 from a loss of 264.2 million yuan in 2022, according to a Tuesday filing with the Shanghai Stock

MT NewswiresApr 16 03:25 ET

Tasly (600535.SH) reported 2023 annual results, with net profit of 1,071 billion yuan, turning a year-on-year loss into a profit

Tasly (600535.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 86...

Zhitong FinanceApr 15 05:30 ET

Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Top Owners Are Private Companies With 49% Stake, While 41% Is Held by Individual Investors

Key Insights The considerable ownership by private companies in Tasly Pharmaceutical Group indicates that they collectively have a greater say in management and business strategy The top 4 sharehold

Simply Wall StMar 29 20:15 ET